Consistently with its involvement in Alt-NHEJ repair, our group also provided pre-clinical evidence indicating that PARP1 is up-regulated in MM patients, where it associated to poor outcome, and notably, that PARP1 knockdown or its pharmacological inhibition by Olaparib led to anti-MM activity in vitro and in vivo [62]. Here, PARP1 is linked to Miyoshi myopathy.